Orthocell Overview
- Year Founded
-
2006
- Status
-
Public
- Stock Symbol
-
OCC
- Investments
-
2
- Share Price
-
$0.37
- (As of Tuesday Closing)
Orthocell General Information
Description
Orthocell Ltd is engaged in the development, manufacture and commercialisation of collagen-based medical devices and cell therapies for the repair and regeneration of bone, nerve, tendon and cartilage defects. It has one segment regenerative medicine industry in Australia with products sold in Australia and internationally. Its solutions are Remplier, Striate, and Cell Therapies.
Contact Information
Website
www.orthocell.comCorporate Office
- Building 191 Murdoch University
- South Street
- Murdoch, Western Australia 6150
- Australia
Corporate Office
- Building 191 Murdoch University
- South Street
- Murdoch, Western Australia 6150
- Australia
Orthocell Timeline
Orthocell Stock Performance
As of 17-Nov-2026, Orthocell’s stock price is $0.37. Its current market cap is $102M with 272M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.37 | $0.39 | $0.34 - $0.80 | $102M | 272M | 381K |
Orthocell Financials Summary
As of 30-Sep-2026, Orthocell has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 115,589 | 105,655 | 167,050 | 36,874 |
| Revenue | 7,728 | 4,885 | 3,483 | |
| EBITDA | (10,172) | (7,215) | (6,327) | |
| Net Income | (9,426) | (5,543) | (4,706) | |
| Total Assets | 37,718 | 23,016 | 17,790 | |
| Total Debt | 668 | 377 | 461 |
Orthocell Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Orthocell Comparisons
Industry
Financing
Details
Orthocell Competitors (4)
One of Orthocell’s 4 competitors is Organogenesis Holdings, a Pending Transaction (M&A) company based in Canton, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Organogenesis Holdings | Pending Transaction (M&A) | Canton, MA | ||||
| Taxus Cardium Pharmaceuticals Group | Formerly VC-backed | San Diego, CA | ||||
| Mimedx Group | Corporation | Marietta, GA | ||||
| Sofregen | Venture Capital-Backed | Framingham, MA |
Orthocell Patents
Orthocell Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022406427-A1 | Cellular composition and uses thereof | Pending | 06-Dec-2021 | ||
| CA-3240318-A1 | Cellular composition and uses thereof | Pending | 06-Dec-2021 | ||
| EP-4444868-A1 | Cellular composition and uses thereof | Pending | 06-Dec-2021 | ||
| EP-4444868-A4 | Cellular composition and uses thereof | Pending | 06-Dec-2021 | ||
| US-20230174943-A1 | Cellular composition and uses thereof | Pending | 06-Dec-2021 | C12N5/066 |
Orthocell Investments (2)
Orthocell’s most recent deal was a Corporate with Marine Biomedical for . The deal was made on 16-Jan-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Marine Biomedical | 16-Jan-2026 | Corporate | Therapeutic Devices | ||
| The University of Western Australia (Ortho ATI Intellectual Property) | 12-May-2014 | Corporate Asset Purchase | Buildings and Property |
Orthocell ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Orthocell FAQs
-
When was Orthocell founded?
Orthocell was founded in 2006.
-
Where is Orthocell headquartered?
Orthocell is headquartered in Murdoch, Australia.
-
What industry is Orthocell in?
Orthocell’s primary industry is Drug Discovery.
-
Is Orthocell a private or public company?
Orthocell is a Public company.
-
What is Orthocell’s stock symbol?
The ticker symbol for Orthocell is OCC.
-
What is the current stock price of Orthocell?
As of 17-Nov-2026 the stock price of Orthocell is $0.37.
-
What is the current market cap of Orthocell?
The current market capitalization of Orthocell is $102M.
-
Who are Orthocell’s competitors?
Organogenesis Holdings, Taxus Cardium Pharmaceuticals Group, Mimedx Group, and Sofregen are competitors of Orthocell.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process